Dose-response Study of Exendin-9,39 on Glucose Metabolism

Completed · Phase 1

Conditions studied: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1

In brief

Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.

Key facts

Study ID
NCT01218633
Run by
Adrian Vella
People needed
11
Starts
2011-05-01
Expected to finish
2012-12-01
Last updated by the study team
2013-01-23

Who can join

Age: 20 and older, up to 45. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.